Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 7/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 2/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE1A | P54750 | 1/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23558166 | 0.87 | TLR7 (0.43) | GRIN1GRIN2BTLR7 | |
| SCHEMBL29824826 | 0.78 | GAA (0.37) | GRIN2BSRC | |
| SCHEMBL23531654 | 0.78 | GAA (0.37) | GRIN2BSRC | |
| SCHEMBL23558376 | 0.78 | MEN1 (0.43) | GRIN2BCDK1SRCRAPGEF4PRKCA | |
| SCHEMBL29824869 | 0.78 | FPR2 (0.38) | GRIN1GRIN2BCDK1SRCPRKCA | |
| SCHEMBL23531684 | 0.78 | FPR2 (0.38) | GRIN1GRIN2BCDK1SRCPRKCA | |
| SCHEMBL29824911 | 0.77 | ABL1 (0.37) | GRIN1GRIN2BSRC | |
| SCHEMBL23558170 | 0.77 | ABL1 (0.37) | GRIN1GRIN2BSRC | |
| SCHEMBL23558167 | 0.76 | GRIN2B (0.45) | GRIN1GRIN2B | |
| SCHEMBL23557924 | 0.75 | GRIN2B (0.49) | GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230099293-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | US | disclosed |
| EP-4077323-A1 | OGA INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2022-10-26 | — | — | EP | disclosed |
| CN-114867725-A | OGA inhibitor compounds | 詹森药业有限公司 | 2022-08-05 | — | — | CN | disclosed |
| WO-2021123294-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230099293-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | GRIN1 490/4885GRIN2B 614/4885TLR7 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.